Antigua and Barbuda vs British Virgin Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Antigua and Barbuda
0.2%
in 2024
British Virgin Islands
0.2%
in 2024
Antigua and Barbuda rank
98th
British Virgin Islands rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Antigua and Barbuda
- British Virgin Islands
How they compare
Antigua and Barbuda currently reports 0.2% against 0.2% in British Virgin Islands, a difference of 0.0%.
Across all 10 years both countries report, British Virgin Islands has been ahead every year.
Antigua and Barbuda ranks 98th and British Virgin Islands ranks 98th of 246 countries.
Head to head by decade
| Decade | Antigua and Barbuda | British Virgin Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Antigua and Barbuda or British Virgin Islands?
- Antigua and Barbuda, at 0.2% against 0.2% in British Virgin Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Antigua and Barbuda and British Virgin Islands?
- 0.0%, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and British Virgin Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do Antigua and Barbuda and British Virgin Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Antigua and Barbuda ranks 98th and British Virgin Islands ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.